By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Cornerstone Pharmaceuticals, Inc. 

1 Duncan Drive

Cranbury  New Jersey  08512  U.S.A.
Phone: 609-409-7050 Fax: 609-409-6035


SEARCH JOBS


Industry
Pharmaceutical






Company News
Cornerstone Pharmaceuticals, Inc. Initiates Phase I Clinical Trial Of CPI-613 For The Treatment Of Hodgkin's Or T-Cell Non-Hodgkin's Lymphoma 10/21/2014 10:40:45 AM
Cornerstone Pharmaceuticals, Inc. Appoints Steve Carchedi CEO 10/10/2014 7:10:25 AM
Cornerstone Pharmaceuticals, Inc.' CPI-613 Phase I Hematologic Malignancies Trial Data Published In Clinical Cancer Research 10/7/2014 7:55:15 AM
Cornerstone Pharmaceuticals, Inc. Lead Compound CPI-613 Demonstrates Ability To Disrupt Growth Of Cancer Cells 3/13/2014 9:28:44 AM
Cornerstone Pharmaceuticals, Inc. Presents Updated Phase I Data For CPI-613 At 2013 American Society of Hematology Annual Meeting 12/10/2013 9:29:41 AM
Cornerstone Pharmaceuticals, Inc. to Present CPI-613 Phase I Results at 2013 American Society of Hematology Annual Meeting 11/11/2013 11:49:29 AM
Cornerstone Pharmaceuticals, Inc. Announces Initiation of Phase 2 Clinical Trial of CPI-613 in Patients With Locally Advanced or Metastatic Pancreatic Cancer 10/31/2013 9:46:04 AM
Cornerstone Pharmaceuticals, Inc. Receives FDA Orphan Drug Designation of CPI-613 for Treatment of Myelodysplastic Syndrome 10/3/2013 10:04:49 AM
Cornerstone Pharmaceuticals, Inc. Initiates Phase 2 Clinical Trial of CPI-613 for the Treatment of Myelodysplastic Syndrome 9/25/2013 9:09:52 AM
Cornerstone Pharmaceuticals, Inc.' Cancer Metabolism Inhibitor, CPI-613, Showing Promise in Phase I Trial for Acute Myeloid Leukemia 12/12/2011 11:56:19 AM
123
//-->